BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22497450)

  • 21. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.
    Lee KJ; Choe BH; Choe JY; Kim JY; Jeong IS; Kim JW; Yang HR; Chang JY; Kim KM; Moon JS; Ko JS
    J Korean Med Sci; 2018 Feb; 33(8):e63. PubMed ID: 29441755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
    Li X; Gao F; Liu H; Zhang H; Liu Y; Ye X; Geng M; Sun L; Wang R; Li Y; Jiang Y; Wang X; Zhou G; Yang Z; Li A; Zeng H; Wang X
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):1-9. PubMed ID: 27749778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Huang G; Yang Y; Shen F; Pan ZY; Fu SY; Lau WY; Zhou WP; Wu MC
    Ann Surg Oncol; 2013 May; 20(5):1482-90. PubMed ID: 23247982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
    Kim BG; Jung SW; Kim EH; Kim JH; Park JH; Sung SJ; Park BR; Kim MH; Kim CJ; Lee BU; Park JH; Jeong ID; Bang SJ; Shin JW; Park NH
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1514-21. PubMed ID: 25973716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
    Park JG; Lee YR; Park SY; Lee HJ; Tak WY; Kweon YO; Jang SY; Chun JM; Han YS; Hur K; Lee HW; Kang MK
    Dig Liver Dis; 2018 Feb; 50(2):163-167. PubMed ID: 29089265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
    Lee SJ; Yim HJ; Hwang SG; Seo YS; Kim JH; Yoon EL; Lee JM; Kim BH; Park SJ; Park YM; Kim HS; Lee SH; Ahn SH; Lee JI; Lee JW; Kim IH; Kim HS; Hong SP
    Scand J Gastroenterol; 2013 Feb; 48(2):196-204. PubMed ID: 23194375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.
    Jun CH; Hong HJ; Chung MW; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
    World J Gastroenterol; 2013 Oct; 19(40):6834-41. PubMed ID: 24187458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
    J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.